View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBenevolentAI 過去の業績過去 基準チェック /06BenevolentAIは4.2%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで8.5%毎年増加している。売上は減少しており、年平均55.8%の割合である。主要情報4.19%収益成長率121.60%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率-55.80%株主資本利益率-73.07%ネット・マージン-1,056.02%前回の決算情報30 Jun 2024最近の業績更新Reported Earnings • Sep 25First half 2024 earnings released: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)First half 2024 results: UK£0.20 loss per share (improved from UK£0.31 loss in 1H 2023). Net loss: UK£24.8m (loss narrowed 32% from 1H 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024Reported Earnings • Mar 18Full year 2023 earnings released: UK£0.54 loss per share (vs UK£1.50 loss in FY 2022)Full year 2023 results: UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022). Net loss: UK£63.3m (loss narrowed 61% from FY 2022). Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.すべての更新を表示Recent updatesお知らせ • Mar 14BenevolentAI Announces Delisting from Euronext Amsterdam Effective 13 March 2025BenevolentAI S.A. announced that their shares will be delisted from Euronext Amsterdam effective 13 March 2025.お知らせ • Feb 08BenevolentAI S.A. Proposes Delisting from Euronext Amsterdam N.VFollowing the announcement on 11 December 2024 and subsequent further detailed review and evaluation, the Board of BenevolentAI S.A. has concluded that delisting from Euronext Amsterdam N.V. (“Euronext”) and transitioning to a private company is in the best interests of the Company and its shareholders. The Board determined that the financial and administrative costs of maintaining a public listing are not justified by the benefits. By eliminating the significant costs associated with its public status, including legal, regulatory, financial, and administrative overheads, the Company can redeploy this capital towards core business activities that drive innovation and product development. This aims to deliver greater value to its shareholders, partners and ultimately benefit the patients it serves. The proposed Delisting and Merger of BenevolentAI into Osaka Holdings requires passing EGM Resolutions (as defined and set out below). It is important for shareholders to understand that should any of the Resolutions fail to pass, the Delisting and Merger will not proceed. Delisting will be implemented via a merger of BenevolentAI into Osaka Holdings. Osaka Holdings is currently a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg. It is not listed on any exchange and has no assets and no liabilities other than its share capital which will be reduced to zero on Merger. Upon the Merger, scheduled for completion on 12 March 2025, all the Company’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession. If the Resolutions are passed at the EGM, the Merger will become effective once both BenevolentAI and Osaka Holdings have adopted the concurring approval decisions during their respective general meetings on the same day. Consequently, it is envisaged that the Delisting will become effective on 13 March 2025. Upon Delisting, the last day of trading in the class A shares and class A warrants will be 12 March 2025. The EGM will be held on 12 March 2025.お知らせ • Oct 17+ 1 more updateBenevolentAI S.A. Appoints Michael Brennan as Chief Financial OfficerBenevolentAI announced the appointment of Michael Brennan as Chief Financial Officer, further strengthening the Company’s leadership. A co-founder of BenevolentAI, Michael brings a wealth of expertise from senior roles across the biotechnology, technology and investment banking sectors. His appointment reflects the Company’s focus on strengthening its commercial and financial position and driving future growth.Reported Earnings • Sep 25First half 2024 earnings released: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)First half 2024 results: UK£0.20 loss per share (improved from UK£0.31 loss in 1H 2023). Net loss: UK£24.8m (loss narrowed 32% from 1H 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.New Risk • Sep 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£16m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€86.6m market cap, or US$96.6m).Breakeven Date Change • Sep 19Forecast to breakeven in 2026The 4 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2025. The company is expected to make a profit of UK£713.4k in 2026. Average annual earnings growth of 58% is required to achieve expected profit on schedule.お知らせ • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: UK£63m Forecast net loss in 3 years: UK£9.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (UK£9.9m net loss in 3 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€70.2m market cap, or US$78.3m).お知らせ • Jul 04BenevolentAI S.A. Announces CFO ChangesBenevolentAI S.A. announced a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week’s successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company’s leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.Breakeven Date Change • May 29Forecast to breakeven in 2026The 3 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2025. The company is expected to make a profit of UK£1.25m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule.お知らせ • May 03Benevolentai S.A. Announces Directorate ChangesBenevolentAI announced that all resolutions proposed at its Annual General Meeting were duly passed. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executive Directors. As per the Company’s announcement of 15 April 2024, the close of the AGM has also resulted in the resignations of Dr François Nader, Dr Olivier Brandicourt, Dr Susan Liautaud and Mr. Marcello Damiani, as Non-Executive Directors of BenevolentAI, becoming effective. The Board now consists of eight persons, seven Non-Executive Directors and Dr Joerg Moeller, CEO and Executive Director of the Company. The position of the Chair of the Board and the composition of Board Committees will be determined at the time of the first board meeting and will be communicated thereafter.お知らせ • Apr 15BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company’s AGM on 2 May 2024.お知らせ • Apr 03Kenneth Mulvany Sends a Letter to Benovelent AIOn April 2, 2024, Kenneth Mulvany stated that he has sent a letter to Benovelent AI, stating that he has raised concerns about the Company's cost management, business development resourcing, strategy, investor relations and governance. In addition, Kenneth Mulvany stated that in his letter he declared his intention to nominate a slate of director candidates that aim to strengthen governance and accountability, invigorate the Company's business development, sharpen its strategic focus, offer clear market communication, and rebuild confidence among our investors and stakeholders, and this declaration paves the way for him to seek the support of shareholders at the forthcoming Annual General Meeting, for Board reform. Further, Kenneth Mulvany stated that he will be focusing the Board's efforts to prioritize stringent cost management and revenue growth, along with expanding strategic partnerships and with the support of shareholders, he prepared to take on a director role.お知らせ • Mar 20+ 1 more updateBenevolentAI S.A., Annual General Meeting, May 02, 2024BenevolentAI S.A., Annual General Meeting, May 02, 2024, at 14:00 Central European Standard Time. Location: 2, place Winston Churchill, L-1340 LuxembourgNew Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£12m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€89.6m market cap, or US$97.4m).Reported Earnings • Mar 18Full year 2023 earnings released: UK£0.54 loss per share (vs UK£1.50 loss in FY 2022)Full year 2023 results: UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022). Net loss: UK£63.3m (loss narrowed 61% from FY 2022). Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.Board Change • Mar 07High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Francois Nader is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.収支内訳BenevolentAI の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:2XA 収益、費用、利益 ( )GBP Millions日付収益収益G+A経費研究開発費30 Jun 245-51224431 Mar 246-57235131 Dec 237-63235730 Sep 239-61196330 Jun 2311-59146931 Mar 2311-112697131 Dec 2211-1641257230 Sep 229-1861416930 Jun 228-2081576631 Mar 226-1581066131 Dec 215-108565731 Dec 207-55522031 Dec 195-48412131 Dec 187-27400質の高い収益: 2XAは現在利益が出ていません。利益率の向上: 2XAは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 2XAは利益を出していないが、過去 5 年間で年間4.2%の割合で損失を削減してきた。成長の加速: 2XAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 2XAは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 15.1% ) と比較することは困難です。株主資本利益率高いROE: 2XAは現在利益が出ていないため、自己資本利益率 ( -73.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/03/17 01:48終値2025/03/12 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BenevolentAI S.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Rajan SharmaGoldman SachsRichard VosserJ.P. MorganJames GordonJ.P. Morgan1 その他のアナリストを表示
Reported Earnings • Sep 25First half 2024 earnings released: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)First half 2024 results: UK£0.20 loss per share (improved from UK£0.31 loss in 1H 2023). Net loss: UK£24.8m (loss narrowed 32% from 1H 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024
Reported Earnings • Mar 18Full year 2023 earnings released: UK£0.54 loss per share (vs UK£1.50 loss in FY 2022)Full year 2023 results: UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022). Net loss: UK£63.3m (loss narrowed 61% from FY 2022). Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Mar 14BenevolentAI Announces Delisting from Euronext Amsterdam Effective 13 March 2025BenevolentAI S.A. announced that their shares will be delisted from Euronext Amsterdam effective 13 March 2025.
お知らせ • Feb 08BenevolentAI S.A. Proposes Delisting from Euronext Amsterdam N.VFollowing the announcement on 11 December 2024 and subsequent further detailed review and evaluation, the Board of BenevolentAI S.A. has concluded that delisting from Euronext Amsterdam N.V. (“Euronext”) and transitioning to a private company is in the best interests of the Company and its shareholders. The Board determined that the financial and administrative costs of maintaining a public listing are not justified by the benefits. By eliminating the significant costs associated with its public status, including legal, regulatory, financial, and administrative overheads, the Company can redeploy this capital towards core business activities that drive innovation and product development. This aims to deliver greater value to its shareholders, partners and ultimately benefit the patients it serves. The proposed Delisting and Merger of BenevolentAI into Osaka Holdings requires passing EGM Resolutions (as defined and set out below). It is important for shareholders to understand that should any of the Resolutions fail to pass, the Delisting and Merger will not proceed. Delisting will be implemented via a merger of BenevolentAI into Osaka Holdings. Osaka Holdings is currently a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg. It is not listed on any exchange and has no assets and no liabilities other than its share capital which will be reduced to zero on Merger. Upon the Merger, scheduled for completion on 12 March 2025, all the Company’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession. If the Resolutions are passed at the EGM, the Merger will become effective once both BenevolentAI and Osaka Holdings have adopted the concurring approval decisions during their respective general meetings on the same day. Consequently, it is envisaged that the Delisting will become effective on 13 March 2025. Upon Delisting, the last day of trading in the class A shares and class A warrants will be 12 March 2025. The EGM will be held on 12 March 2025.
お知らせ • Oct 17+ 1 more updateBenevolentAI S.A. Appoints Michael Brennan as Chief Financial OfficerBenevolentAI announced the appointment of Michael Brennan as Chief Financial Officer, further strengthening the Company’s leadership. A co-founder of BenevolentAI, Michael brings a wealth of expertise from senior roles across the biotechnology, technology and investment banking sectors. His appointment reflects the Company’s focus on strengthening its commercial and financial position and driving future growth.
Reported Earnings • Sep 25First half 2024 earnings released: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)First half 2024 results: UK£0.20 loss per share (improved from UK£0.31 loss in 1H 2023). Net loss: UK£24.8m (loss narrowed 32% from 1H 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.
New Risk • Sep 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£16m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€86.6m market cap, or US$96.6m).
Breakeven Date Change • Sep 19Forecast to breakeven in 2026The 4 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2025. The company is expected to make a profit of UK£713.4k in 2026. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
お知らせ • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024
New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: UK£63m Forecast net loss in 3 years: UK£9.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (UK£9.9m net loss in 3 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€70.2m market cap, or US$78.3m).
お知らせ • Jul 04BenevolentAI S.A. Announces CFO ChangesBenevolentAI S.A. announced a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week’s successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company’s leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.
Breakeven Date Change • May 29Forecast to breakeven in 2026The 3 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2025. The company is expected to make a profit of UK£1.25m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
お知らせ • May 03Benevolentai S.A. Announces Directorate ChangesBenevolentAI announced that all resolutions proposed at its Annual General Meeting were duly passed. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executive Directors. As per the Company’s announcement of 15 April 2024, the close of the AGM has also resulted in the resignations of Dr François Nader, Dr Olivier Brandicourt, Dr Susan Liautaud and Mr. Marcello Damiani, as Non-Executive Directors of BenevolentAI, becoming effective. The Board now consists of eight persons, seven Non-Executive Directors and Dr Joerg Moeller, CEO and Executive Director of the Company. The position of the Chair of the Board and the composition of Board Committees will be determined at the time of the first board meeting and will be communicated thereafter.
お知らせ • Apr 15BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company’s AGM on 2 May 2024.
お知らせ • Apr 03Kenneth Mulvany Sends a Letter to Benovelent AIOn April 2, 2024, Kenneth Mulvany stated that he has sent a letter to Benovelent AI, stating that he has raised concerns about the Company's cost management, business development resourcing, strategy, investor relations and governance. In addition, Kenneth Mulvany stated that in his letter he declared his intention to nominate a slate of director candidates that aim to strengthen governance and accountability, invigorate the Company's business development, sharpen its strategic focus, offer clear market communication, and rebuild confidence among our investors and stakeholders, and this declaration paves the way for him to seek the support of shareholders at the forthcoming Annual General Meeting, for Board reform. Further, Kenneth Mulvany stated that he will be focusing the Board's efforts to prioritize stringent cost management and revenue growth, along with expanding strategic partnerships and with the support of shareholders, he prepared to take on a director role.
お知らせ • Mar 20+ 1 more updateBenevolentAI S.A., Annual General Meeting, May 02, 2024BenevolentAI S.A., Annual General Meeting, May 02, 2024, at 14:00 Central European Standard Time. Location: 2, place Winston Churchill, L-1340 Luxembourg
New Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£12m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€89.6m market cap, or US$97.4m).
Reported Earnings • Mar 18Full year 2023 earnings released: UK£0.54 loss per share (vs UK£1.50 loss in FY 2022)Full year 2023 results: UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022). Net loss: UK£63.3m (loss narrowed 61% from FY 2022). Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
Board Change • Mar 07High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Francois Nader is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.